Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acute Lysine Administration and 2-AAA Levels
NCT03063476Phase 1Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Mar 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lysine in type 2 diabetes mellitus (T2DM), sponsored by Vanderbilt University Medical Center. Primary endpoint: Peak Plasma α-aminoadipic Acid Concentration Percentage Change From Baseline at 6 hours. Started Mar 2017; status: completed.
02
Drugs
lysine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03063476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03063476.